212 related articles for article (PubMed ID: 34448628)
21. Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products.
Park H; Jeon J; Kim K; Choi S; Hong S
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803840
[TBL] [Abstract][Full Text] [Related]
22. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel
Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2023 Jul; ():1-13. PubMed ID: 37403288
[TBL] [Abstract][Full Text] [Related]
24. In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics.
Mahata S; Behera SK; Kumar S; Sahoo PK; Sarkar S; Fazil MHUT; Nasare VD
Int J Biol Macromol; 2022 May; 208():356-366. PubMed ID: 35346675
[TBL] [Abstract][Full Text] [Related]
25. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
27. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
28. Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach.
Shao M; Yuan Y; Yu K; Lei K; Zhu G; Chen L; Xiang M
Mol Divers; 2014 May; 18(2):335-44. PubMed ID: 24519385
[TBL] [Abstract][Full Text] [Related]
29. Identification of Pim-1 Kinase Inhibitors by Pharmacophore Model, Molecular Docking-based Virtual Screening, and Biological Evaluation.
Huang J; Yuan Y; Zhu X; Li G; Xu Y; Chen W; Zhu Y
Curr Comput Aided Drug Des; 2022; 18(3):240-246. PubMed ID: 35490326
[TBL] [Abstract][Full Text] [Related]
30. Why target PIM1 for cancer diagnosis and treatment?
Magnuson NS; Wang Z; Ding G; Reeves R
Future Oncol; 2010 Sep; 6(9):1461-78. PubMed ID: 20919829
[TBL] [Abstract][Full Text] [Related]
31. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.
Zhao B; Liu L; Mao J; Zhang Z; Wang Q; Li Q
Cell Death Dis; 2018 Feb; 9(3):307. PubMed ID: 29472550
[TBL] [Abstract][Full Text] [Related]
32. An integrated docking and molecular dynamics simulation approach to discover potential inhibitors of activin receptor-like kinase 1.
Jairajpuri DS; Mohammad T; Hussain A; Amir S; Fatima U; AlAjmi MF; Yadav DK; Hassan MI
J Mol Recognit; 2024 Mar; 37(2):e3069. PubMed ID: 38053481
[TBL] [Abstract][Full Text] [Related]
33. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
34. Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy.
Hassan MI; Anjum D; Mohammad T; Alam M; Khan MS; Shahwan M; Shamsi A; Yadav DK
J Biomol Struct Dyn; 2023 Dec; 41(20):10558-10568. PubMed ID: 36495308
[TBL] [Abstract][Full Text] [Related]
35. Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics.
Anjum F; Sulaimani MN; Shafie A; Mohammad T; Ashraf GM; Bilgrami AL; Alhumaydhi FA; Alsagaby SA; Yadav DK; Hassan MI
RSC Adv; 2022 Mar; 12(13):7872-7882. PubMed ID: 35424745
[TBL] [Abstract][Full Text] [Related]
36. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
37. Identification of Phytoconstituents as Potent Inhibitors of Casein Kinase-1 Alpha Using Virtual Screening and Molecular Dynamics Simulations.
Shafie A; Khan S; Zehra ; Mohammad T; Anjum F; Hasan GM; Yadav DK; Hassan MI
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959438
[TBL] [Abstract][Full Text] [Related]
38. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.
Zhang F; Beharry ZM; Harris TE; Lilly MB; Smith CD; Mahajan S; Kraft AS
Cancer Biol Ther; 2009 May; 8(9):846-53. PubMed ID: 19276681
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.
Ikram N; Mirza MU; Vanmeert M; Froeyen M; Salo-Ahen OMH; Tahir M; Qazi A; Ahmad S
Biomolecules; 2019 Mar; 9(4):. PubMed ID: 30925835
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
